Management of Patients with Genotype 3 Chronic Hepatitis C: Can we Change the Duration of Therapy?

Research output: Chapter in Book/Report/Conference proceedingChapter


Based on the favourable response to peginterferon and ribavirin combination therapy, genotype 2 and genotype 3 HCV infections have been regarded until recently as a single entity. However, due to several factors, patients with genotype 3 HCV infection show consistently lower sustained virological response rates than those observed in patients with genotype 2 infection. Recently, week 4 on-treatment response emerged as the most relevant predictor of sustained virological response and it was suggested as the criterion on which to base the reduction of treatment length for patients infected with genotype 2 and 3 HCV. In the absence of a rapid virological response patients with genotype 3 HCV respond less well than genotype 2 patients, even after 24 weeks of treatment. Advanced liver damage is the most relevant adverse factor among the host- and virus-related factors that are associated with the absence of a rapid virological response or of a poor response after an early response in patients treated with either short or standard courses of antiviral therapy.

Original languageEnglish
Title of host publicationClinical Dilemmas in Viral Liver Disease
Number of pages6
ISBN (Print)9781405179058
Publication statusPublished - Mar 10 2010



  • Advanced liver damage
  • Body mass index
  • Genotype 3
  • Rapid virological response
  • Sustained virological response

ASJC Scopus subject areas

  • Medicine(all)

Cite this